ARCHIVES

Regorafenib Trial Meets Primary Endpoint; Overall Survival Improved by 29 Percent

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Reinventing NCI: Clinical Trials System Changes Not Easy Or Quick, Klausner Says; NCAB Members, Others, Sound Off On Group’s Report

October 10, 1997

NCI Plans a Catalog Of Research Tools

April 30, 1999

Hypothyroidism Associated With Reduced Breast Cancer

April 25, 2003

CDC Offers Funds For 5-A-Day Program; CDC PA Available

May 14, 1999

Rituxan Approved as Maintenance For Advanced Follicular Lymphoma

February 25, 2011

DRG Reimbursement Schedules Estimated for High, Low Areas; City Of Hope Added to Exemptions, Other Without Much Hope

November 18, 1983